Challenges and opportunities for improving pre... - CLL Support
Challenges and opportunities for improving precision medicine in CLL outlined in a new review article
You need to be a member of this community to see this post.
Read more about...
11 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Review article summarises management strategies for those with CLL harbouring complex karyotype
On 6 January 2025, the journal BJ Haem published a review article titled Management...
Chronic lymphocytic leukemia treatment algorithm 2022
This 29 November 2022 review article published in the Blood Cancer Journal presents an...
CLLSA and Leukaemia Care Joint Response to NHS England regarding Ibrutinib Prescribing as per NICE TA
This is the letter sent to Professor Peter Clarke on 2nd July 2018 for the review of Ibrutinib...
Venetoclax has been added to the Pharmaceutical Benefits Scheme in Australia for use as a retreatment for CLL/SLL
In more good news, today the Pharmaceutical Benefits Scheme (PBS) in Australia added venetoclax to...
Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis
Given the interest in my recent response to @[571533] about whether our immune system will get...
Related Posts
- Median PFS for FCR treated CLL patients with IGHV-M was 14.6 years vs 4.2 years for patients with IGHV-UM. V+O and I+R look to be superior
- Efficacy and safety of new‑generation BTKis (primarily acalabrutinib and zanubrutinib) in CLL/SLL: a systematic review and meta‑analysis
- Expert Answers to Frequently Asked Questions About Chronic Lymphocytic Leukemia and COVID-19, including vaccination
- BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'
- The current status and challenges of CAR-T therapy in CLL
